Summit Therapeutics Inc Ordinary Shares SMMT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024
-
Summit Therapeutics' stock pops as lung-cancer treatment beats Merck blockbuster in late-stage trial
-
Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China
-
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
HARMONi-2, Featuring Ivonescimab Monotherapy vs. Pembrolizumab Monotherapy, to be Showcased in Presidential Symposium at WCLC 2024
-
Two Ivonescimab (PD-1/VEGF) Results including Phase 3 Monotherapy versus Pembrolizumab Monotherapy in First-Line Treatment for PD-L1 Positive NSCLC to Be Presented at WCLC 2024
-
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2024
Trading Information
- Previous Close Price
- $20.10
- Day Range
- $19.22–20.36
- 52-Week Range
- $1.64–33.89
- Bid/Ask
- $19.39 / $19.43
- Market Cap
- $14.36 Bil
- Volume/Avg
- 4,383 / 4.8 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Core
- Total Number of Employees
- 105
- Website
- https://www.smmttx.com
Comparables
Valuation
|
Metric
|
SMMT
|
KNSA
|
TRVI
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 222.89 | — |
Price/Book Value | 72.55 | 4.01 | 3.50 |
Price/Sales | — | 5.18 | — |
Price/Cash Flow | — | 71.00 | — |
Price/Earnings
SMMT
KNSA
TRVI
Financial Strength
|
Metric
|
SMMT
|
KNSA
|
TRVI
|
|---|---|---|---|
Quick Ratio | 2.33 | 2.84 | 10.29 |
Current Ratio | 2.35 | 3.57 | 10.68 |
Interest Coverage | −13.06 | — | −4,780.89 |
Quick Ratio
SMMT
KNSA
TRVI
Profitability
|
Metric
|
SMMT
|
KNSA
|
TRVI
|
|---|---|---|---|
Return on Assets (Normalized) | −49.56% | 2.27% | −40.88% |
Return on Equity (Normalized) | −108.87% | 2.73% | −44.19% |
Return on Invested Capital (Normalized) | −51.07% | 2.66% | −48.62% |
Return on Assets
SMMT
KNSA
TRVI
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Btyskjhf | Dxlmq | $518.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Vvzvhprc | Xrzpjrt | $119.3 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Ywglkhk | Jhbmsc | $114.7 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Stwpdnztk | Krgctl | $34.9 Bil | |||
| argenx SE ADR
ARGX
| Nxyjfylhs | Strmb | $32.9 Bil | |||
| BioNTech SE ADR
BNTX
| Fxzhvzz | Dtkvf | $28.3 Bil | |||
| Moderna Inc
MRNA
| Mzydqhlsd | Pgpm | $24.3 Bil | |||
| United Therapeutics Corp
UTHR
| Qfbnlvcl | Xwwkl | $15.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Syxwqvxr | Jqcmr | $13.3 Bil | |||
| Incyte Corp
INCY
| Kcgjczztc | Nqqvqvg | $13.0 Bil |
United States